What is Wedbush’s Estimate for argenx FY2026 Earnings?

argenx SE (NASDAQ:ARGX) – Wedbush lowered their FY2026 earnings per share estimates for shares of argenx in a research report issued on Wednesday, November 20th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of $21.65 for the year, down from their previous estimate of $22.14. The consensus estimate for argenx’s current full-year earnings is $2.20 per share. Wedbush also issued estimates for argenx’s FY2027 earnings at $34.77 EPS.

Several other equities analysts have also recently weighed in on ARGX. Evercore ISI raised their price target on shares of argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a research report on Thursday. Wells Fargo & Company raised their target price on argenx from $547.00 to $639.00 and gave the company an “overweight” rating in a report on Friday, November 1st. William Blair upgraded argenx from a “market perform” rating to an “outperform” rating in a report on Friday, November 1st. Truist Financial increased their price target on argenx from $540.00 to $660.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, Piper Sandler lifted their price objective on shares of argenx from $553.00 to $620.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $630.42.

argenx Stock Up 1.5 %

NASDAQ ARGX opened at $605.92 on Friday. argenx has a 52 week low of $327.73 and a 52 week high of $611.22. The business has a 50 day moving average price of $557.73 and a 200-day moving average price of $488.21. The company has a market cap of $36.23 billion, a price-to-earnings ratio of -688.55 and a beta of 0.61.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $0.10 by $1.29. The firm had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same quarter in the prior year, the business earned ($1.25) earnings per share.

Institutional Trading of argenx

Several institutional investors and hedge funds have recently bought and sold shares of the company. Blue Trust Inc. boosted its position in shares of argenx by 620.0% during the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock valued at $28,000 after acquiring an additional 62 shares during the last quarter. J.Safra Asset Management Corp lifted its position in argenx by 590.0% during the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after purchasing an additional 59 shares during the last quarter. GAMMA Investing LLC grew its stake in argenx by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after buying an additional 40 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in argenx in the 2nd quarter worth approximately $76,000. Finally, Cromwell Holdings LLC increased its holdings in shares of argenx by 73.3% in the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after buying an additional 66 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.